
1. emerg infect dis. 2014 oct;20(10):1637-44. doi: 10.3201/eid2010.140411.

effects mefloquine use plasmodium vivax multidrug resistance.

khim n, andrianaranjaka v, popovici j, kim s, ratsimbasoa a, benedet c, barnadas 
c, durand r, thellier m, legrand e, musset l, menegon m, severini c, nour by,
tichit m, bouchier c, mercereau-puijalon o, m√©nard d.

numerous studies indicated strong association amplification the
multidrug resistance-1 gene vivo vitro mefloquine resistance of
plasmodium falciparum. although falciparum infection usually treated 
mefloquine, incorrect diagnosis, high frequency undetected mixed infections,
or relapses p. vivax infection triggered p. falciparum infections expose
non-p. falciparum parasites mefloquine. assess consequences such
unintentional treatments p. vivax, studied variations number pvmdr-1 
(plasmodb accession no. pvx_080100, ncbi reference sequence nc_009915.1) copies
worldwide 607 samples collected areas different histories of
mefloquine use residents travelers returning france. number of
pvmdr-1 copies correlated drug use history. treatment p. falciparum 
exerts substantial collateral pressure sympatric p. vivax, jeopardizing
future use mefloquine p. vivax. drug policy needed takes
into consideration co-endemic species malaria parasites.

doi: 10.3201/eid2010.140411 
pmcid: pmc4193276
pmid: 25272023  [indexed medline]

